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ABSTRACT
Introduction: Viral kinetics has proved useful
in understanding antiviral potency,
determining antiviral profiles and optimizing
treatment strategy.
Methods: This was a randomized, open-label
study comparing the viral kinetics in 46
hepatitis B e antigen-positive patients during
12-week treatment with telbivudine
monotherapy, tenofovir monotherapy or the
combination of telbivudine plus tenofovir. A
standard biphasic mathematical model was
used to compare hepatitis B virus (HBV) DNA
decay parameters.
Results: Forty-six patients received telbivudine
(n = 16), tenofovir (n = 14) or telbivudine plus
tenofovir (n = 16). From baseline to Week 12,
the mean (SD) reduction in HBV DNA levels was
not significantly different between treatment
groups: -3.9 (0.9) log10 copies/mL in
telbivudine group, -4.2 (0.7) log10 copies/mL
in tenofovir group, and -4.4 (1.0) log10 copies/
mL in combination group. No significant
difference was observed among the three
groups for viral clearance rate per day (0.97,
1.02, and 0.88, respectively) or for infected cell
loss rate per day (0.04, 0.05, and 0.05,
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respectively). Antiviral efficiency in blocking viral
production was similar in the monotherapy
groups (median; 99.7% in telbivudine group
and 99.4% in tenofovir group), but was slightly
better and more homogeneous in the
combination treatment group than in the
monotherapy groups: mean (SD), 99.1% (0.8%)
and 98.8% (1.6%), respectively (Wald–Wolfowitz
test; P = 0.038). All treatments were well
tolerated and no serious adverse event was
reported during the study. Of the 46 patients in
the safety population, 23 experienced adverse
events. Most of the adverse events were not
suspected to be related to the study drug by the
investigators.
Conclusion: Monotherapy with telbivudine or
tenofovir showed similar antiviral effectiveness
in HBV DNA reduction and viral kinetics of HBV
DNA decay. Efficiency in blocking viral
production was slightly improved in the
combination treatment group compared to the
monotherapy groups.
Keywords: Chronic hepatitis B; Combination
therapy; Hepatitis B virus; Infectious diseases;
Telbivudine; Tenofovir; Viral kinetics
INTRODUCTION
Long-term suppression of serum hepatitis B
virus (HBV) DNA is likely to reduce
progression to cirrhosis and hepatic
decompensation and to decrease the risk of
hepatocellular carcinoma. Therefore, the
primary goal of therapy for chronic hepatitis B
(CHB) is suppression of viral replication [1–3].
No currently available single medication is
able to achieve both potent HBV DNA
suppression and high rates of hepatitis B e
antigen (HBeAg) and hepatitis B surface
antigen (HBsAg) clearance. Therefore, drug
combination, which is a therapeutic strategy
that has been shown to be successful to reduce
viral resistance in human immunodeficiency
virus (HIV) therapy, attracted some interest in
CHB management. In initial trials evaluating
the combination of pegylated interferon
(PegIFN) and lamivudine, a slightly enhanced
viral suppression and lower resistance rates were
observed with the combination compared with
either drug alone [4–6]. A clear advantage of the
combination over each monotherapy treatment
for long-term outcomes such as HBeAg or
HBsAg seroconversion was not demonstrated.
In vitro, slightly synergistic effects to
additive effects have been suggested for some
combinations of nucleos(t)ides [7–9].
Telbivudine demonstrated additive to weakly
synergistic anti-HBV activity in vitro when
combined with tenofovir or entecavir; there
was no evidence of cytotoxicity [10]. Previously,
mathematical modeling of early HBV kinetics
has been used to examine the efficacy of
combination therapy with dual nucleos(t)ide
analogs, namely famciclovir with lamivudine or
adefovir with emtricitabine [11, 12].
Learning from these studies, the current
investigation was designed to examine the
effect of a combination of more potent
antiviral agents, telbivudine and tenofovir
disoproxil for chronic HBV infection. Unlike
previous studies [13–16], immunotolerant
patients were studied so as to avoid the
interference of host immune system on the
understanding of whether there is any true
synergistic effect. These studies included
lamivudine in the combination and
demonstrated limited clinical benefit over
monotherapy for virological endpoints [17–
19]. Analysis of resistance demonstrated that
combination of lamivudine with another
nucleoside or PegIFN was associated with
lower resistance rates to lamivudine [5, 6, 18,
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19]. Nevertheless, current practice guidelines do
not recommend combination of nucleos(t)ides
as first-line treatment [1–3].
With the newest nucleosides/nucleotides
such as telbivudine, tenofovir or entecavir,
clinical trials comparing combination therapy
with monotherapy are needed before
combination therapy can be recommended as
first-line therapy. The present study aimed to
assess whether the combination therapy with
telbivudine plus tenofovir has superior antiviral
efficacy on the 1st and 2nd phase of HBV DNA
decay compared to either drug as monotherapy.
In these patients who are not considered as
candidates for CHB therapy according to
international guidelines, we assessed the early
viral kinetics induced by telbivudine plus
tenofovir combination therapy versus
telbivudine or tenofovir monotherapy.
Assessment of early viral kinetics provides
critically important information in
understanding antiviral potency, determining
antiviral profiles and developing treatment
strategy [13, 20, 21]. We used mathematical
modeling of viral kinetics to compare HBV DNA
decay parameters during initial 12-week
treatment with telbivudine monotherapy,
tenofovir monotherapy, or combination of
telbivudine plus tenofovir.
METHODS
Study Design and Patients
This randomized, open-label, controlled,
exploratory study assessed the reduction in
HBV DNA level in patients with HBeAg-
positive CHB treated with telbivudine
monotherapy, tenofovir monotherapy, or
combination of telbivudine plus tenofovir.
In total, 46 previously untreated patients
with HBeAg-positive chronic HBV infection
[with HBV DNA C107 log10 copies/mL and
alanine aminotransferase (ALT) B1 9 upper
limit of normal (ULN)] were randomized
(1:1:1) to receive a daily dose of telbivudine
600 mg or tenofovir disoproxil fumarate 300 mg
or telbivudine plus tenofovir combination for
12 weeks (Table 1). Block randomization was
used to maintain balance to each treatment
group. After 12-week treatment, at the
discretion of the investigator, patients would
be continued for a further 36-week antiviral
therapy or 12-week follow-up phase.
The study enrolled male and female patients
of 18–40 years of age with documented
HBeAg-positive CHB [defined as positive serum
HBsAg for at least 6 months or HBsAg
positive[3 months and with negative
immunoglobulin M (IgM) anti-hepatitis B core
antibody (HBc) and positive immunoglobulin G
(IgG) anti-HBc], HBV DNA levels C7 log10
copies/mL by COBAS TaqMan HBV DNA
assay (Roche, Basel, Switzerland) and serum
ALT levels B1 9 ULN.
Key exclusion criteria were history of or
clinical signs or symptoms of hepatic
decompensation, prior treatment with
interferon therapy within 6 months,
a-fetoprotein[50 ng/mL, evidence of
hepatocellular carcinoma, coinfection with
HIV-1 or hepatitis C or D virus, prior oral HBV
therapy, significant renal, cardiovascular,
pulmonary or neurological disease, calculated
creatinine clearance\70 mL/min (Cockroft–
Gault equation), solid organ or bone marrow
transplantation, treatment by any
immunomodulatory treatment, hemoglobin
level\10 g/dL, absolute neutrophil count
\1,500 mm3, proximal tubulopathy, medical
condition that required prolonged or frequent
use of systemic acyclovir or famciclovir.
Women who were pregnant, breastfeeding, or
of child-bearing potential and not using
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acceptable methods of birth control were also
ineligible.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. This study was approved by
local independent Ethics Committee. Informed
consent was obtained from all patients for
being included in the study.
Efficacy Assessments
Efficacy assessments included serum HBV DNA,
HBeAg, antibodies to HBeAg, and ALT levels
which were obtained at screening, baseline (Day
1 before dosing), Days 2, 4, 6, 8, 11, 15 (Week 2),
22 (Week 3), 29 (Week 4), 43 (Week 6), 57 (Week
8), and 85 (Week 12) and post-treatment follow-
up visits at post-baseline Day 113 (Week 16), Day
141 (Week 20) and Day 169 (Week 24). The
primary objective of the study was to
characterize the reduction in HBV DNA level
from baseline to Week 12 of telbivudine
monotherapy, tenofovir monotherapy, and
telbivudine plus tenofovir combination therapy.
The secondary objective was to characterize early
viral kinetics through estimation of various
parameters including efficiency of blocking new
virus production and half-lives of free virions
and infected hepatocytes.
HBV DNA Quantification
Serum of patients was collected for HBV DNA
measurement at baseline and at all scheduled
visits. Serum HBV DNA determinations were
conducted at a central laboratory using COBAS
TaqMan HBV DNA assay, which utilizes the
real-time polymerase chain reaction.
Viral Kinetics
Viral kinetic parameters were estimated with a
biphasic mathematical model of HBV DNA
using compartments of free virus, infected cells
and uninfected target cells [14, 22, 23]. The
differential equation system of the underlying
biphasic model of viral kinetics was as follows:
V 0 tð Þ ¼ 1  eð ÞpI tð ÞcV tð Þ and I 0 tð Þ
¼ 1  gð Þb Tg  I tð Þ
 
V tð Þ  dI tð Þ
where V denotes serum viral load, I productively
infected cells, e the efficiency factor of blocking
virus production, p the viral production rate, c
the viral clearance rate, g the efficiency factor of
blocking de novo infection, b the de novo
infection rate, Tg comprises all infected and
uninfected target cells, and d the rate of infected
cell loss [13, 14, 22].
Maximum-likelihood estimation methods
for the viral kinetic parameters c, e, and d
entailed the fitting of a nonlinear differential
equation system via the least-squares approach
from the serum HBV DNA data collected during
the treatment period. In addition, g = 0.5 was
used as in previous analyses and the viral kinetic
parameters for p and b can be derived from the
others when assuming a steady state before
treatment starts. MATLAB (MathWorks Inc.,
Natick, MA, USA) routines were used to
calculate these estimates.
Safety Assessment
Vital signs, physical examination and
laboratory parameters were collected at
screening, baseline and at all scheduled visits.
All adverse events and serious adverse events
were reported with their severity and
relationship to the study drug.
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Statistical Analysis
All efficacy assessments were performed on the
intent-to-treat population, which consisted of
all patients who had been randomized and had
received at least one dose of study drug.
Kruskal–Wallis test and nonparametric Wald–
Wolfowitz test were used to compare the data
and to assess data variability, respectively. The
safety population consisted of patients that had
been randomized and had taken at least one
dose of the study drug. All statistical tests were
bilateral with a 0.05 alpha level of significance.
RESULTS
Patient Disposition
Forty-seven patients met the inclusion/
exclusion criteria (Table 1). One patient
withdrew consent and 46 patients were
randomized and included in the intent-to-treat
analysis. All 46 randomized patients completed
the 12-week treatment except one patient in the
combination group who discontinued at Week 1
due to an adverse event (nausea and dyspepsia).
Treatment groups were comparable at baseline
except the percentage of men, which was slightly
lower in the telbivudine plus tenofovir
combination group (38%) compared to the
telbivudine group (56%) or to the tenofovir
group (64%). HBV DNA levels at baseline were
comparable between the three treatment groups.
Mean (SD) exposure to study drugs was
comparable between treatment groups: 84.6
(1.8) days in telbivudine group, 84.8 (1.7) days
in tenofovir group, and 80.1 (19.7) days in
telbivudine plus tenofovir group. The
compliance of drug intake in the two
monotherapy arms was similar and slightly
less in the combination arm.
HBV DNA Decline
The mean HBV DNA reduction in the three
treatment arms was almost identical (Fig. 1). As
soon as Day 2, the mean decrease of HBV DNA
level was -0.53 log10 copies/mL in telbivudine
group, -0.58 log10 copies/mL in tenofovir group
and -0.54 log10 copies/mL in combination group.
Since Week 3, the mean (SD) HBV DNA
reduction was numerically higher in the
combination group compared to the
monotherapy groups: telbivudine plus







Age, mean (SD), years 28.0 (7.6) 27.3 (4.9) 28.9 (5.6)
Gender, n (%)
Male 9 (56) 9 (64) 6 (38)
Female 7 (44) 5 (36) 10 (63)
Asian (Chinese) patients, n (%) 16 (100) 14 (100) 16 (100)
HBeAg-positive, n (%) 16 (100) 14 (100) 16 (100)
Baseline HBV DNA, mean (SD), log10 copies/mL 8.98 (0.59) 8.78 (0.87) 8.89 (0.60)
Baseline ALT level, mean (SD), IU/L 31.6 (12.8) 33.9 (18.6) 33.3 (21.2)
ALT Alanine aminotransferase, HBeAg Hepatitis B e antigen, HBV Hepatitis B virus, SD Standard deviation
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tenofovir, -3.1 (0.7) log10 copies/mL; as
compared to -2.9 (0.9) log10 copies/mL in
telbivudine monotherapy group and -2.9 (0.6)
log10 copies/mL in tenofovir monotherapy
group. At Week 12, the greater HBV DNA
reduction in the combination group persisted
with mean (SD) decrease of -4.4 (1.0) log10
copies/mL in the combination group compared
to -3.9 (0.9) log10 copies/mL in telbivudine
group and -4.2 (0.7) log10 copies/mL in
tenofovir group (Fig. 1). Combination
treatment provided slightly more decrease of
HBV DNA copies from baseline to Week 12 than
telbivudine or tenofovir. However, the
differences between the three groups did not
achieve statistical significance.
One female patient of 40 years of age in the
combination group achieved undetectable
serum HBV DNA (\169 copies/mL) and
became HBeAg negative at Week 12. This
patient had a medical history of compensated
CHB and at baseline HBV DNA level was
28,750,800 copies/mL and ALT level was
61 IU/L.
Viral Kinetics
The data supported the biphasic model for viral
kinetics and no patient showed deviation from
the biphasic pattern. There were no significant
differences between the three groups in terms of
viral clearance rate per day (parameter c: 0.97
for telbivudine, 1.02 for tenofovir, and 0.88 for
telbivudine plus tenofovir) or infected cell loss
rate per day (parameter d: 0.04, 0.05, and 0.05,
respectively; Table 2).
Efficiency in blocking viral production
(e parameter) was not significantly different
between the two monotherapy groups (median







































Fig. 1 Mean HBV DNA decline over time by treatment groups (intent-to-treat population). Error bars are standard
deviations. HBV Hepatitis B virus
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tenofovir group; Kruskal–Wallis test; Table 2).
This viral kinetics parameter was more
homogeneous in the combination treatment
group than in the monotherapy groups: mean
(SD), 99.1% (0.8%) and 98.8% (1.6%),
respectively (Wald–Wolfowitz test; P = 0.038).
Figure 2 shows that first-phase log decay of
virus was overall comparable in the three groups.
Data in the telbivudine group showed a slightly
higher median value compared to tenofovir
monotherapy or combination treatment group.
Furthermore, the minimum and maximum
values of the combination treatment group
were higher than the other treatment groups.
Safety
All treatments were well tolerated and no
serious adverse event was reported during the
study. The adverse events reported were
expected for this study population and class
of drug. Of the 46 patients in the safety
population, 23 experienced adverse events (16
events in telbivudine, 14 in tenofovir, and 16 in







Viral clearance rate/day, c
Median 0.97 1.02 0.88
Range 0.52–1.25 0.66–2.87 0.51–3.75
Infected cell loss rate/day, d
Median 0.04 0.05 0.05
Range 0.01–0.07 0.03–0.09 0.01–0.10
Efﬁciency factor of blocking virus production, e (%)
Median 99.7 99.4 99.5
Range 94.7–99.9 94.6–99.8 97.6–99.95
Half-life of free virus (h)
Median 17.1 16.5 18.9
Range 13.3–32.2 5.8–25.2 4.4–32.8
Half-life of infected cells (days)
Median 16.2 12.9 14.1
























Fig. 2 Box-plots for the ﬁrst-phase decay of viral kinetics
by treatment groups (intent-to-treat population). The
boxes show the ranges of estimated ﬁrst-phase log decay
between the 25% and 75% quartiles; the median is shown
by the line and the vertical lines represent the range (the
smallest and largest values in each group)
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combination group). The commonly reported
adverse events were nausea (12.5%) and
influenza (12.5%) in combination group;
influenza (31.3%) and influenza-like illness
(25%) in telbivudine group; influenza (21.4%),
influenza-like illness (14.3%), and upper
abdominal pain (14.3%) in tenofovir group,
respectively.
Most of the adverse events were considered
as not suspected to be related to study drug by
investigators. Adverse events reported to be
related to study drug were dizziness (n = 1;
drug combination), dyspepsia (n = 1; drug
combination), nausea (n = 2; drug
combination), upper abdominal pain (n = 1;
tenofovir), and somnolence (n = 1; tenofovir).
Two muscle-related adverse events were
reported. None were considered to be drug
related. One was reported in the tenofovir group
(mild ‘‘lower limb muscle cramp’’) and the other
was reported in the tenofovir and telbivudine
combination group (mild ‘‘neck stiffness’’).
No renal-related adverse event was reported
during the study. There was no significant
change in the mean glomerular filtration rate
[modification of diet in renal disease (MDRD)
formula] in all 3 groups.
No patient at baseline had grade 3–4 creatine
kinase abnormality or during the course of the
study. Three patients (one in each of the three
treatment groups) experienced ALT
elevation C2 9 baseline (and C2 9 ULN) during
the study period. ALT levels elevated and
reached peak approximately at Week 6 or
Week 8 and decreased along with time without
drug discontinuation. All three patients have
completed 12-week study treatment period.
DISCUSSION
This study provides the first head-to-head
comparison of the viral kinetics profiles of
telbivudine 600 mg/day and tenofovir 300 mg/
day for treatment-naı¨ve patients with HBeAg-
positive CHB. There was a comparable early
reduction in mean HBV DNA levels over time in
both monotherapy groups.
Differences in treatment responses have
been related to different factors such as HBV
genotype, baseline ALT level, HBeAg status,
previous treatment history for CHB or drug
pharmacokinetics [14, 24, 25]. In addition, it
has been shown that distinct patterns of viral
kinetics are associated to different antiviral
treatments [25]. Thus, we used a biphasic
model that allowed comparisons with other
recent trials aimed to characterize the early
viral kinetics during treatment of CHB. In this
biphasic model, the viral kinetics depends of
three parameters during the first month of
treatment. The effectiveness (e) of blocking
virion production is estimated by the first
phase of DNA decline; the half-life of the free
virions (c) is estimated by the first-phase slope
and the half-life of infected cells (d) is estimated
from second-phase slope. The modeling of CHB
infection under treatment is expected to
predict long-term prediction of antiviral
response with the hope that future researches
will allow to define individualized treatments
according to early viral kinetics parameters
[14, 26–28].
The authors’ analysis of the early viral
kinetics during the first weeks after treatment
initiation is consistent with previous data [13–
16]. During the 12 weeks of treatment, a
biphasic decline of HBV DNA was observed:
the first phase consisted in a rapid decline in
HBV DNA levels for approximately 2 weeks,
followed by a second phase with a less rapid
steady decrease in HBV DNA levels. The viral
kinetic parameters were comparable between
the two monotherapy groups with respect to
viral clearance per day, rate of infected cell loss
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per day, and efficiency of blocking viral
replication.
This viral kinetics study demonstrates that
telbivudine and tenofovir have the same
potency. Similar results were reported in a
previous published study by Suh et al. [13]
comparing telbivudine versus entecavir which
showed similar potency between entecavir and
telbivudine. The 12-week study by Suh et al.
[13] in HBeAg-positive patients (with
ALT C1.3 9 ULN) has shown equal potency in
an analysis comparing the viral kinetics
parameters with telbivudine (HBV DNA
reduction, -6.6 ± 1.6 log10 copies/mL) versus
entecavir (-6.5 ± 1.5 log10 copies/mL)
treatment. There were no significant
differences between groups for mean values of
viral clearance by day, loss of infected cells per
day or efficiency of blocking viral production.
Consistent with this previous study, we report
that the HBV DNA decrease was evident as soon
as Day 2 after treatment initiation and was
sustained during the 12-week treatment. The
mean estimate of efficiency in blocking viral
production (99.7%) was also consistent with the
mean estimate of efficiency reported by Suh
et al. [13] (99.1%).
Another study comparing telbivudine and
entecavir for early response has been
reported by Shi et al. [29] in HBeAg-positive
patients. This study confirmed earlier results
showing no difference in the mean reduction
in HBV DNA levels between the treatment
groups (-5.27 log10 copies/mL for
telbivudine and -5.36 log10 copies/mL for
entecavir) [29]. Of interest, Shi et al. [29]
have studied the relationship between the
early and profound suppression of HBV DNA
and the HBeAg seroconversion rate. These
authors observed that, despite that HBeAg
seroconversion is usually a rare event during
the first 3 months of treatment with
nucleos(t)ide treatment, higher rates of
HBeAg seroconversion were achieved in
telbivudine-treated patients compared to
entecavir-treated patients at Week 12 (20%
vs. 5%, respectively; P = 0.043) and Week 24
(27.5% vs. 17.5%; P[0.05) [29]. To explain
this finding, an additional mechanism of
action for telbivudine in the suppression of
HBV replication has been suggested.
Preliminary results suggest that telbivudine
could exert antiviral effect not only directly
by inhibiting viral replication, but also by
stimulating the host immune system [30–32].
Further studies are necessary to confirm that
this effect on the immune system contributes
to the high HBeAg seroconversion rates
reported in long-term studies in
telbivudine-treated HBeAg-positive patients
[33–35].
In the current study, both monotherapies
had similar reduction [-4.374 (telbivudine ?
tenofovir) vs. -3.852 (telbivudine) vs. -4.175
(tenofovir) log10 copies/mL], however, these
differences did not achieve statistical
significance (for tenofovir vs. telbivudine ?
tenofovir). In the telbivudine plus tenofovir
combination group, there was an additional
benefit in HBV DNA reduction at Week 12. This
was supported by the more homogeneous
efficiency of blocking viral replication in this
combination group. Although these differences
did not achieve statistical significance, the
limitation of the study to 12 weeks did not
allow evidencing an improvement of this
difference after Week 12. Tenofovir use may be
limited by nephrotoxicity especially in patient
with high renal risk. Prospective and
retrospective data on telbivudine suggest that
telbivudine may have potential renal protective
action as estimated by MDRD, mainly in patient
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with high renal risk (older, nephrotoxic agents,
transplant) [36]. All these evidences support the
use of this combination as potential optimal
combination regimens.
Furthermore, in the GLOBE trial
(ClinicalTrials.gov #NCT00057265), the
proportions of telbivudine-treated patients
with undetectable HBV DNA increased
markedly between treatment weeks 12 and
24: from 19% to 45% in HBeAg-positive
patients [37]. Moreover, in the GLOBE trial,
all outcomes at 2 years of HBeAg-positive
patients were improved for patients with
undetectable HBV DNA levels at treatment
week 12 or week 24: the difference was
particularly marked after comparison with
patients with serum HBV DNA[4 log10
copies/mL [38].
The safety and tolerability of the treatment
in this study were favorable. No patient
experienced renal function impairment; there
were no significant changes in the mean
glomerular filtration rate compared with
baseline in the three groups.
CONCLUSION
This viral kinetics study demonstrates that viral
kinetics parameters were comparable between
the telbivudine and tenofovir groups with
respect to viral clearance per day, rate of
infected cell loss per day and efficiency of
blocking viral replication. First-phase decay of
virus in the telbivudine group showed a slightly
higher median value. The telbivudine and
tenofovir combination group showed
additional benefit in HBV DNA reduction at
Week 12. This was supported by the more
homogeneous efficiency of blocking viral
replication in telbivudine and tenofovir
combination group.
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